Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM and Q1 trading statement

7 Aug 2020 07:00

RNS Number : 4230V
Scapa Group PLC
07 August 2020
 

 

7 August 2020

 

LEI No. 213800QIPVTK5ES5UU36

 

Scapa Group plc

 

AGM and Q1 trading statement

 

 

AGM

Scapa Group plc (AIM: SCPA) is holding its Annual General Meeting (AGM) at 10:00am today. As stated in the Notice of AGM, this year's AGM is a closed meeting due to COVID-19 restrictions in place. While shareholders are unable to attend in person, they are able to submit questions pertaining to the AGM business via investors@scapa.com. The results of the AGM will be published later today.

 

Q1 Trading Update

Scapa has delivered FY21 Q1 revenues in the three months to 30 June 2020 well ahead of its COVID-19 scenario plan. Trading in both divisions has also continued to improve into FY21 Q2 to date. Scapa acted swiftly to implement structural costs changes across the business in response to the impact of the COVID-19 pandemic on the reduction in product demand, as well as ensuring variable costs were closely managed to match the new demand levels.

 

Working capital management remains strong, with adjusted net debt¹ at the end of FY21 Q1 of £18.4m (including net proceeds of £31.6m from the equity placement in May 2020), compared to the FY20 year-end position of £54.4m.

 

The combination of the better than anticipated business performance in FY21 to date, early cost intervention measures and continued improvement across both divisions mean the Group's outlook on full year trading profit is trending approximately 10% ahead of market expectations.

 

1 Adjusted net debt excludes the IFRS16 impact of lease liabilities

 

 

For further information:

 

Scapa Group plc

Heejae Chae - Group Chief Executive

Oskar Zahn - Chief Financial Officer

 

Tel: 0161 301 7430

Numis Securities Limited

(Nominated Adviser/Joint Broker)

 

Mark Lander, Freddie Barnfield

Tel: 020 7260 1000

Berenberg

(Joint Broker)

 

Chris Bowman, Toby Flaux

 

Tel: 020 3207 7800

FTI Consulting

(Media Relations)

 

Simon Conway, Victoria Foster Mitchell

Tel: 020 3727 1000

 

About Scapa Group plc

Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

 

Healthcare

Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

For further information, please visit www.scapahealthcare.com

 

Industrial

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

For further information, please visit www.scapaindustrial.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMSSUFMMESSESA
Date   Source Headline
1st Mar 201710:22 amRNSAdditional Listing
23rd Feb 201711:03 amRNSHolding(s) in Company
16th Feb 20179:21 amRNSHolding(s) in Company
7th Feb 20174:16 pmRNSBlock listing Interim Review
3rd Feb 20173:53 pmRNSHolding(s) in Company
26th Jan 201710:10 amRNSDirector/PDMR Shareholding
25th Jan 20174:33 pmRNSBlock listing Interim Review
25th Jan 201711:49 amRNSHolding(s) in Company
23rd Jan 20179:18 amRNSDirector/PDMR Shareholding
9th Jan 20179:41 amRNSAdditional Listing
22nd Dec 20162:15 pmRNSAdditional Listing
15th Dec 20167:00 amRNSDirectorate Change
13th Dec 20161:29 pmRNSAdditional Listing
24th Nov 20164:30 pmRNSDirector/PDMR Shareholding
24th Nov 20164:20 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:20 pmRNSAdditional Listing
22nd Nov 20167:00 amRNSHalf-year Report
12th Oct 20167:00 amRNSTrading Statement
27th Sep 20162:53 pmRNSDirector/PDMR Shareholding
21st Sep 20161:51 pmRNSAdditional Listing
6th Sep 201610:24 amRNSAdditional Listing
2nd Sep 201611:20 amRNSBlock listing Interim Review
31st Aug 20169:14 amRNSTotal Voting Rights
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
12th Aug 201611:24 amRNSBlock listing Interim Review
11th Aug 20161:30 pmRNSDirector/PDMR Shareholding
10th Aug 201610:08 amRNSDirector/PDMR Shareholding
19th Jul 20164:58 pmRNSAdditional Listing
19th Jul 20167:00 amRNSAGM Statement
11th Jul 20163:48 pmRNSDirector/PDMR Shareholding
5th Jul 20162:25 pmRNSHolding(s) in Company
1st Jul 20162:58 pmRNSDirector/PDMR Shareholding
1st Jun 20163:49 pmRNSAdditional Listing
1st Jun 20167:00 amRNSAppointment of Joint Broker
24th May 20167:00 amRNSFinal Results
24th May 20167:00 amRNSAcquisition
18th May 201610:01 amRNSAdditional Listing
11th May 201610:45 amRNSHolding(s) in Company
18th Apr 20167:00 amRNSDirectorate Change
14th Apr 20167:00 amRNSTrading Statement
2nd Mar 20169:06 amRNSBlocklisting Interim Review
8th Feb 20169:49 amRNSBlocklisting Interim Review
28th Jan 20167:00 amRNSDirectorate Change
31st Dec 20157:00 amRNSTotal Voting Rights
15th Dec 20159:57 amRNSHolding(s) in Company
14th Dec 20158:26 amRNSHolding(s) in Company
14th Dec 20158:21 amRNSDirector/PDMR Shareholding
8th Dec 201511:46 amRNSHolding(s) in Company
8th Dec 201511:42 amRNSHolding(s) in Company
1st Dec 201510:52 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.